Cargando…

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

Oncogenic Ras mutants, frequently detected in human cancers, are high-priority anticancer drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has been extremely challenging. Here we report the development of a human IgG1 format antibody, RT11, which internalizes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Seung-Min, Choi, Dong-Ki, Jung, Keunok, Bae, Jeomil, Kim, Ji-sun, Park, Seong-wook, Song, Ki-Hoon, Kim, Yong-Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436137/ https://www.ncbi.nlm.nih.gov/pubmed/28489072 http://dx.doi.org/10.1038/ncomms15090

Ejemplares similares

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies
por: Rinis, Natalie, et al.
Publicado: (2014)

Mutations of K-ras oncogene in human adrenal tumours in Taiwan.
por: Lin, S. R., et al.
Publicado: (1998)

The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo
por: Rackley, Briana, et al.
Publicado: (2021)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum.
por: Spandidos, D. A., et al.
Publicado: (1984)

Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism
por: Zhou, Ge, et al.
Publicado: (2014)

The Importance of Mg(2+)‐Free State in Nucleotide Exchange of Oncogenic K‐Ras Mutants
por: Pálfy, Gyula, et al.
Publicado: (2022)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth
por: Chabu, Chiswili, et al.
Publicado: (2017)

Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line
por: Tokunaga, T, et al.
Publicado: (2000)

ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant
por: Tago, Kenji, et al.
Publicado: (2017)

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
por: Khan, Imran, et al.
Publicado: (2022)

Oncogenic N-Ras Stimulates SRF-Mediated Transactivation via H3 Acetylation at Lysine 9
por: Yi, Sun-Ju, et al.
Publicado: (2018)

Immunohistochemical detection of the ras oncogene p21 product in an experimental tumour and in human colorectal neoplasms.
por: Williams, A. R., et al.
Publicado: (1985)

Involvement of Autophagy in Oncogenic K-Ras-induced Malignant Cell Transformation
por: Kim, Min-Jung, et al.
Publicado: (2011)

Oncogenic Ras mutant causes the hyperactivation of NF‐κB via acceleration of its transcriptional activation
por: Tago, Kenji, et al.
Publicado: (2019)

Transforming ras oncogenes and multistage carcinogenesis.
por: Balmain, A.
Publicado: (1985)

Ras oncogene mutation in multiple myeloma
Publicado: (1989)

RAS: Striking at the Core of the Oncogenic Circuitry
por: Gimple, Ryan C., et al.
Publicado: (2019)

Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014)

286 Association Analysis of Member RAS Oncogene Family Gene Polymorphisms with Aspirin Intolerance in Asthmatic Patients
por: Kim, Myung ok, et al.
Publicado: (2012)

Colonic Mucosal Necrosis Following Administration of Calcium Polystryrene Sulfonate (Kalimate) in a Uremic Patient
por: Joo, Mee, et al.
Publicado: (2009)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression.
por: Wyllie, A. H., et al.
Publicado: (1987)

Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity
por: Kim, Jung-Eun, et al.
Publicado: (2019)

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway
por: Wu, C-H, et al.
Publicado: (2002)

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
por: Kadosh, Eliran, et al.
Publicado: (2020)

The role of RAS oncogenes in controlling epithelial mechanics
por: Nyga, Agata, et al.
Publicado: (2023)

Hyperphosphorylated PTEN exerts oncogenic properties
por: van Ree, Janine H., et al.
Publicado: (2023)

Decreased GTPase activity of K- ras mutants deriving from human functional adrenocortical tumours
por: Lin, S-R, et al.
Publicado: (2000)

Comparison of liver oncogenic potential among human RAS isoforms
por: Chung, Sook In, et al.
Publicado: (2016)

Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum.
por: Kerr, I. B., et al.
Publicado: (1985)

Protein Fractions from Korean Mistletoe (Viscum Album coloratum) Extract Induce Insulin Secretion from Pancreatic Beta Cells
por: Kim, Ki-Wook, et al.
Publicado: (2014)

Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death
por: Schott, Christina, et al.
Publicado: (2015)

A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
por: Cheng, Rongjie, et al.
Publicado: (2022)

Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer
por: Kim, Su-Jeong, et al.
Publicado: (2023)

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
por: Jeng, Hao-Hsuan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mt2mqk5n23j2vn7nnqpa44ko4c